Preclinical Development of Novel Therapeutics Targeting Aging Mechanisms (SBIR U44 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) utilizes the SBIR cooperative agreement (U44) activity code to support the preclinical development of emerging therapeutics targeting fundamental mechanisms of aging (e.g., inflammation, cell senescence, proteostasis).

This includes the translation of
a broad range of potential geroscience-based therapies, such as new classes of compounds (e.g., senolytics), biologics, stem/progenitor cell-based therapies, repositioning of existing investigational drugs, and repurposing of Food and Drug Administration (FDA)-approved drugs for the treatment and prevention of clinical conditions related to aging and common in the aged.

Examples of translational research activities eligible under this FOA include target validation, optimization of lead compounds, pharmacokinetics and drug disposition studies, as well as preclinical safety/toxicology studies.
Related Programs

Aging Research

Department of Health and Human Services


Agency: Department of Health and Human Services

Office: National Institutes of Health

Estimated Funding: $3,500,000


Who's Eligible



Obtain Full Opportunity Text:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-026.html

Additional Information of Eligibility:
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

Non-domestic (non-U.S.) components of U. S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

see the funding announcement for eligibility details

Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-026.html

Contact:


Agency Email Description:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Agency Email:


Date Posted:
2020-06-25

Application Due Date:


Archive Date:
2020-12-16




301 Moved Permanently

Moved Permanently

The document has moved here.